3rd Quarter - Report

BUCHANAN INGERSOLL & ROONEY PC for AIM IMMUNOTECH INC.

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. FY 2022 Appropriations for Defense Department, and National Institutes of Health (NIH)

LobbyistCovered position, as disclosed
KYLE A DARBY New —
MICHAEL P STRAZZELLA —
JAMES C WILTRAUT —

Contacted: Navy, Dept of; Natl Institutes of Health (NIH); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD); SENATE

Pharmacy PHA

Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. FY 2022 Appropriations for Defense Department, and National Institutes of Health (NIH)

LobbyistCovered position, as disclosed
KYLE A DARBY New —
MICHAEL P STRAZZELLA —
JAMES C WILTRAUT —

Contacted: HOUSE OF REPRESENTATIVES; Navy, Dept of; Natl Institutes of Health (NIH); Defense, Dept of (DOD); SENATE; Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.